Form 8-K - Current report:
SEC Accession No. 0001493152-19-018180
Filing Date
2019-11-21
Accepted
2019-11-21 16:22:51
Documents
5
Period of Report
2019-11-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm 8-K 50720
2 ex10-1.htm EX-10.1 122697
3 ex10-2.htm EX-10.2 60122
4 ex10-3.htm EX-10.3 18680
5 ex10-1_001.jpg GRAPHIC 4085
  Complete submission text file 0001493152-19-018180.txt   259641
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51353 | Film No.: 191237666
SIC: 7389 Services-Business Services, NEC